Basic Information
BioVaxys is a clinical-stage biopharmaceutical company developing antiviral and anticancer vaccine platforms. The company is evaluating a potential SARS-CoV-2 vaccine based on its gasified viral protein technology and advancing compassionate use trials in the EU to assess its gasified cell vaccine for advanced ovarian cancer.
BioVaxys Technology Corporation
Vancouver,Washington,United States of America
less than 15 people
January 01, 2018
info@biovaxys.com
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios